Animal Model for Glucocorticoid Induced Osteoporosis: A Systematic Review from 2011 to 2021

Int J Mol Sci. 2021 Dec 29;23(1):377. doi: 10.3390/ijms23010377.

Abstract

Clinical and experimental data have shown that prolonged exposure to GCs leads to bone loss and increases fracture risk. Special attention has been given to existing emerging drugs that can prevent and treat glucocorticoid-induced osteoporosis GIOP. However, there is no consensus about the most relevant animal model treatments on GIOP. In this systematic review, we aimed to examine animal models of GIOP centering on study design, drug dose, timing and size of the experimental groups, allocation concealment, and outcome measures. The present review was written according to the PRISMA 2020 statement. Literature searches were performed in the PubMed electronic database via Mesh with the publication date set between April, 2011, and February 2021. A total of 284 full-text articles were screened and 53 were analyzed. The most common animal species used to model GIOP were rats (66%) and mice (32%). In mice studies, males (58%) were preferred and genetically modified animals accounted for 28%. Our work calls for a standardization of the establishment of the GIOP animal model with better precision for model selection. A described reporting design, conduction, and selection of outcome measures are recommended.

Keywords: animal models; bone; bone loss; dexamethasone; glucocorticoid induced osteoporosis; methylprednisolone; therapy.

Publication types

  • Systematic Review

MeSH terms

  • Animals
  • Biomechanical Phenomena / drug effects
  • Bone Resorption / pathology
  • Bone and Bones / drug effects
  • Bone and Bones / pathology
  • Disease Models, Animal
  • Female
  • Glucocorticoids / adverse effects*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Osteoporosis / chemically induced*
  • Osteoporosis / pathology*
  • Rats
  • Rats, Sprague-Dawley

Substances

  • Glucocorticoids